Bioventus Inc. 是一家医疗器械公司,专注于在美国及国际范围内开发并商业化能够参与并增强人体自然愈合过程的临床治疗。公司总部位于北卡罗来纳州达勒姆。
财务指标
营业收入
2026-06-30
$1.53亿
2026-03-31
$1.32亿
2025-12-31
$1.57亿
2025-09-30
$1.38亿
营业支出
2026-06-30
$8653.9万
2026-03-31
$8077.3万
2025-12-31
$8577.2万
2025-09-30
$8072.7万
净利润
2026-06-30
$3344.1万
2026-03-31
$311.3万
2025-12-31
$1475.5万
2025-09-30
$315.5万
净利润率
2026-06-30
21.82%
2026-03-31
2.35%
2025-12-31
9.34%
2025-09-30
2.27%
每股收益
2026-06-30
$0.22
2026-03-31
$0.15
2025-12-31
$0.24
2025-09-30
$0.15
息税折旧摊销前利润
2026-06-30
$3032.1万
2026-03-31
$2004.8万
2025-12-31
$3114.3万
2025-09-30
$2225万
有效税率
2026-06-30
-136.51%
2026-03-31
12.64%
2025-12-31
-22.44%
2025-09-30
14.21%
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$1.53亿
$1.32亿
$1.57亿
$1.38亿
营业支出
$8653.9万
$8077.3万
$8577.2万
$8072.7万
净利润
$3344.1万
$311.3万
$1475.5万
$315.5万
净利润率
21.82%
2.35%
9.34%
2.27%
每股收益
$0.22
$0.15
$0.24
$0.15
息税折旧摊销前利润
$3032.1万
$2004.8万
$3114.3万
$2225万
有效税率
-136.51%
12.64%
-22.44%
14.21%
常见问题
BVS stock refers to the publicly traded shares of a company that uses the ticker symbol BVS. The ticker is the short identifier investors type into brokerage platforms and financial websites to access real-time quotes, charts, and company filings. Because BVS is a specific U.S.-listed security, its profile page provides the most current details on the underlying business, exchange listing, and market data. Investors can use that page to confirm the exact company represented by BVS before researching further.
The industry classification for BVS depends on the company behind the ticker and is typically listed in its stock profile and regulatory filings. Sector and industry labels help investors compare BVS with peers, understand its business model, and assess sector-specific risks. The most accurate and current industry designation for BVS is shown on the stock detail page, where it is grouped alongside other companies in the same line of business.
Recent performance for BVS is best measured using the latest price change, percentage move, and short-term chart shown on its stock detail page. These figures update throughout the trading day, so any specific number quoted here could quickly become outdated. Investors often compare BVS's recent return with relevant market indexes and sector peers to judge relative strength, but the most reliable current performance data is the live quote displayed for BVS.
Evaluating BVS's valuation involves reviewing metrics such as the price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, and enterprise value relative to EBITDA. These figures are most useful when compared with BVS's own historical averages and with industry peers. Because valuation multiples change with price and earnings, the current metrics for BVS should be taken from the stock detail page rather than assumed. The goal is to judge whether the market price reflects the company's financial fundamentals.
Risks for BVS include company-specific factors such as competitive pressure, execution challenges, leverage, and dependence on key products or customers. Broader risks may include sector downturns, regulatory changes, interest rate shifts, and general market volatility. Because BVS operates in a particular industry, its risk profile also reflects that industry's cycles and cost structure. Investors can review BVS's risk factor disclosures and financial statements for a fuller picture of these potential threats.
Researching BVS starts with its stock detail page, which consolidates price data, performance charts, valuation metrics, and company information. Investors can then review BVS's quarterly and annual reports, earnings releases, and investor presentations for financial statements and management commentary. Comparing BVS with industry peers and tracking news that affects its sector can add context. Using several sources helps build a balanced view rather than relying on a single data point.